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The 2006 report by the Institute of Medicine (IOM), titled
“Organ Donation, Opportunities for Action” (1) estimated
that 22 000 of the 335 000 individuals who die annually
from cardiac arrest outside of a medical facility would be
suitable for organ donation. Currently donation after car-
diac death (DCD) in the United States usually occurs in
Maastricht Type 3 donors that die after planned withdrawal
of futile cardiorespiratory support in a hospital setting. This
has also been termed “controlled” DCD because the tim-
ing of the donation event is planned. Maastricht Type 2
DCD, termed “uncontrolled” because the timing of the do-
nation event is unplanned, occurs when an individual suf-
fers cardiac arrest outside of a hospital, receives cardiopul-
monary resuscitation en route to a medical facility, but the
attempted resuscitation is unsuccessful and death is de-
clared by circulatory criteria. The IOM report suggested
that the expansion of Type 2 DCD in the United States
should be an imperative.
The IOM also recommended that the term “uncontrolled
DCD” be discouraged because it can be misunderstood to
imply a lack of procedure or protocol. Rather the terms
DCDD for “donation after circulatory determination of
death” and DNDD for ‘donation after neurological deter-
mination of death’ were advocated because they make
it clear that there are two acceptable methods of deter-
mining death—either no circulation, or no brain function.
These terms have neither caught on in the organ donation
nor in the Transplant community. The circulatory definition
of death was recommended because “cardiac death” is a
less precise term. Death of the cardiac tissue has not nec-
essarily occurred at the moment that asystole occurs and
restoration of the flow of oxygenated blood through coro-
nary circulation may restore cardiac function. The most
impressive demonstration of this is the fact that hearts
have been used from donors that were said to have had
“cardiac death”.
There are two major hurdles to the development of Type 2
DCDwithin theUnited States; one is practical and the other
is medical. The practical problem is the enormous amount
of effort and coordinated engagement on the part of mul-
tiple parties that traditionally are not involved with organ
donation that is necessary to develop such programs. In
parts of Spain, the Transplant community has invested this
effort and organs from Type 2 DCD are becoming a nontriv-
ial portion of all organs available for transplantation there,
particularly kidneys. The second barrier is the medical con-
cern about warm ischemia. The concern over ischemia is
particularly great for liver grafts because of the devastat-
ing complication of biliary cholangiopathy (2). To alleviate
this concern, the Barcelona group has applied normother-
mic extracorporeal membrane oxygenation (ECMO) in the
setting of Type 2 organ donation. It is notable that this
protocol was developed in Spain, a country that already
excels in organ donation effectiveness, as measured by
donors per million. This is a testament both to the support
of the Spanish populace for donation and for the dedication
of the Spanish medical community.
In this issue, the Barcelona group report on 34 liver trans-
plants performed over an 8 year period from Type 2 DCD
(3). Their protocol involves the initiation of ECMO after ces-
sation of cardiac massage. They observed 1-year graft and
patient survivals of 71% and 80%, respectively, results
that are comparable to results of liver transplantation from
Type 3 DCD but below that obtained with livers from brain
dead donors. Importantly, only three patients (8%) in this
series developed ischemic cholangiopathy, a comfortingly
low number.
Normothermic ECMO has also been used to support Type
3 DCD with excellent results (4) and offers logistical advan-
tages over a rapid recovery technique. These advantages
include a reduction in warm ischemia time due to the fact
that oxygenated flow to the organs can be restored at the
moment death is declared, rather than waiting until the
abdomen has been opened and the aorta cannulated and
clamped. This advantage is small if the withdrawal of sup-
port occurs in an operating room but greater if the with-
drawal occurs elsewhere or if rapid aortic cannulation is
not possible for technical reasons. The use of postmortem
ECMO also allows withdrawal of support to occur in an
intensive care unit setting without compromising organ
quality. Although promising, it is not yet clear whether the
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benefit of ECMO justifies the complexity and cost in the
Type 3 DCD setting. However, in the Type 2 setting it is
logical that ECMO will be necessary to achieve accept-
able degrees of warm ischemia. The Barcelona group has
demonstrated this elegantly with animal models (5).
Two elements of the Barcelona protocol raise potential eth-
ical dilemmas and will doubtlessly require modification to
be adopted in the United States. One is that the Barcelona
protocol allows cannulation of the patient before family
consent while cardiopulmonary resuscitation (CPR) is on-
going. Although this can be viewed as preserving the pa-
tient’s option of donation, it was the IOM’s stated view that
consent should be obtained before invasive procedures are
performed solely in the name of organ donation on patients
that are still alive. This problem could be obviated however,
if the donor has provided first-person consent for organ do-
nation by signing up on a state registry, in that case permis-
sion of the family is not needed. It is also possible that fam-
ily consent may be attainable before the end of attempted
resuscitation.
The second element that is problematic about the
Barcelona protocol is that cardiac massage and ventila-
tion are continued after the declaration of death to avoid
warm ischemia before the initiation of ECMO. Again, it
can be argued that this is acceptable because it preserves
the option of donation. However, many would argue that
the resumption of circulation to the brain would mean that
the patient is no longer officially dead if the IOM definition
equating death to the absence of circulation to the brain
is used, because circulation to the brain has resumed with
CPR. ECMO too would generate the same concern for
DCD if used without an aortic occlusion balloon to prevent
circulation to the brain. Given that a 5 min period of asys-
tole is allowed before CPR is resumed in the Barcelona
protocol, it is very likely that whole brain function would be
absent if it were possible to test for it after CPR resumes.
Nevertheless, it is unpalatable to assume that the patient
is brain dead when brain function has not been formally
assessed.
A potential modification to the Barcelona protocol that
would avoid this conundrum would be to begin cannula-
tion for ECMO immediately upon declaration of death. This
would avoid the resumption of CPR and, thus, avoid brain
perfusion. However, it would be necessary to have the
ECMO team ready and waiting very nearby and cannula-
tionwould have to be by cut down on the femoral vessels in
the absence of blood flow. Alternatively, the patient could
be ‘redeclared’ dead at the time that CPR ceases, some-
thing that is bound to be prohibitively confusing to medical
teams and families.
The Barcelona group is to be congratulated for developing
and demonstrating a successful strategy for the use of
Type 2 donors. However, reproducing this level of success
in the United States will require a large and coordinated
effort from the medical community as a whole to satisfy
the ethical and cultural concerns.
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